

(12) PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 199524541 B2**
(10) Patent No. **701436**

(54) Title
Hymenialdisine and derivative thereof, process for producing intermediate for synthesizing the same, and said intermediate

(51)⁶ International Patent Classification(s)
C07D 487/04 A61K 031/55

(21) Application No: **199524541** (22) Application Date: **1995 .05 .17**

(87) WIPO No: **WO95/31462**

(30) Priority Data

(31) Number	(32) Date	(33) Country
6-104030	1994 .05 .18	JP

(43) Publication Date : **1995 .12 .05**

(43) Publication Journal Date : **1996 .01 .18**

(44) Accepted Journal Date : **1999 .01 .28**

(71) Applicant(s)
Suntory Limited

(72) Inventor(s)
Hirokazu Annoura; Toshio Tatsuoka

(74) Agent/Attorney
GRIFFITH HACK

(56) Related Art
US 4729996
JP 62-161786

OPI DATE 05/12/95 APPLN. ID 24541/95
AOJP DATE 18/01/96 PCT NUMBER PCT/JP95/00941




AU9524541

(51) 国際特許分類6 C07D 487/04 // A61K 31/55	A1	(11) 国際公開番号 W095/31462 (43) 国際公開日 1995年11月23日 (23.11.95)
(21) 国際出願番号 PCT/JP95/00941 (22) 国際出願日 1995年5月17日 (17.05.95) (30) 優先権データ 特願平6/104030 1994年5月18日 (18.05.94) JP (71) 出願人 (米国を除くすべての指定国について) サントリー株式会社(SUNTORY LIMITED)[JP/JP] 〒530 大阪府大阪市北区堂島浜2丁目1番40号 Osaka, (JP) (72) 発明者; および (75) 発明者/出願人 (米国についてのみ) 案浦洋一(ANNOURA, Hirokazu)[JP/JP] 〒617 京都府長岡京市長法寺北篠谷16-8 Kyoto, (JP) 立岡敏雄(TATSUOKA, Toshio)[JP/JP] 〒662 兵庫県西宮市上甲東園2-18-27 Hyogo, (JP) (74) 代理人 弁理士 石田 敬, 外(ISHIDA, Takashi et al.) 〒105 東京都港区虎ノ門一丁目8番10号 静光虎ノ門ビル 青和特許法律事務所 Tokyo, (JP)	(81) 指定国 AU, CA, KR, LT, SI, US, 欧州特許(AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). 添付公開書類 国際調査報告書	
(54) Title : HYMENIALDISINE AND DERIVATIVE THEREOF, PROCESS FOR PRODUCING INTERMEDIATE FOR SYNTHESIZING THE SAME, AND SAID INTERMEDIATE (54) 発明の名称 ハイメニアルディシン及びその誘導体並びにそれらの合成中間体の製造法並びにその合成中間体 (I) (57) Abstract Hymenialdisine represented by general formula (I) and a derivative thereof, and a process for producing the same, wherein X ¹ represents halogen or hydrogen. These compounds have a protein kinase C inhibitory effect and are expected as a remedy for diseases wherein protein kinase C activation is thought to participate.		

(57) 要約

本発明は、

式(I):



(式中、X¹ はハロゲン原子または水素原子を示す。)

で表されるハイメニアルディシン及びその誘導体並びにその製造方法である。また、それらの合成中間体も本発明である。ハイメニアルディシン及びその誘導体はプロテインキナーゼCの阻害作用を有し、プロテインキナーゼCの活性化が関与すると考えられる病態の治療薬としての用途が期待されている。

情報としての用途のみ

PCTに基づいて公開される国際出願をパンフレット第一頁にPCT加盟国を特定するために使用されるコード


AM	アルメニア	EE	エストニア	LK	スリランカ	RU	ロシア連邦
AT	オーストリア	ES	スペイン	LR	リベリア	SD	スーダン
AU	オーストラリア	FI	フィンランド	LT	リトアニア	SE	スウェーデン
BB	バルバドス	FR	フランス	LU	ルクセンブルグ	SG	シンガポール
BE	ベルギー	GA	ガボン	LV	ラトヴィア	SI	スロヴェニア
BF	ブルキナ・ファソ	GB	イギリス	MC	モナコ	SK	スロヴァキア共和国
BG	ブルガリア	GE	グルジア	MD	モルドバ	SN	セネガル
BJ	ベナン	GN	ギニア	MG	マダガスカル	SZ	スワジランド
BR	ブラジル	GR	ギリシャ	ML	マリ	TD	チャード
BY	ベラルーシ	HU	ハンガリー	MN	モンゴル	TG	トーゴ
CA	カナダ	IE	アイルランド	MR	モーリタニア	TJ	タジキスタン
CF	中央アフリカ共和国	IS	アイスランド	MW	マラウイ	TM	トルクメニスタン
CG	コンゴ	IT	イタリア	MX	メキシコ	TT	トリニダード・トバゴ
CH	スイス	JP	日本	NE	ニジェール	UG	ウガンダ
CI	コート・ジボアール	KE	ケニア	NL	オランダ	UA	ウクライナ
CM	カメルーン	KG	キルギスタン	NO	ノルウェー	UZ	ウズベキスタン共和国
CN	中国	KR	朝鮮民主主義人民共和国	NZ	ニュージーランド	VN	ベトナム
CZ	チェコ共和国	KZ	カザフスタン	PL	ポーランド		
DE	ドイツ	LI	リヒテンシュタイン	PT	ポルトガル		
DK	デンマーク			RO	ルーマニア		

ABSTRACT

The present invention provides hymenialdisine or its derivatives having the formula (I):

5

10



15

20


(wherein X¹ is a halogen atom or a hydrogen atom and a process for production of the same. Further, synthetic intermediates are included in the invention. Hymenialdisine and its derivatives have inhibitory effects against protein kinase C and can be expected to have applications as a drug for the treatment of conditions where it is believed the activation of protein kinase C is involved.)

DESCRIPTION

Synthetic Method of Hymenialdisine and Its
Derivatives and Their Synthetic Intermediates, and
Those Synthetic Intermediates

TECHNICAL FIELD

The present invention relates to a process of
producing of hymenialdisine, its derivatives, and their
salts of the formula (I):



(wherein X¹ is a halogen atom or hydrogen atom.) The
present invention further relates to intermediates for
producing the above compound (I) and processes for
producing the same.

BACKGROUND ART

In recent years, there have been intense exploration
and study of bioactive substances derived from the sea.
Among these, useful substances holding forth promise as
pharmaceuticals and lead compounds for pharmaceuticals
have been discovered. For example, hymenialdisine and
debromohymenialdisine have been isolated from sponges.

For example, hymenialdisine has been isolated from
Axinella verrucosa, Acanthella aurantiaca (Cimino, G. et
al: Tetrahedron Lett., 23, 767 (1982)), Hymeniacidon
aldis (Kitagawa, I. et al: Chem. Pharm. Bull., 31, 2321
(1983)), and an unconfirmed Kololevu sponge (Schmitz, F.
et al: J. Nat. Prod., 48, 47 (1985)), while

debromohymenialdisine has been isolated from Phakellia flabellata (Sharma, G. et al: J. Chem. Soc., Chem. Commun., 435 (1980)) and Hymeniacidon aldis (Kitagawa, I. et al: Chem. Pharm. Bull., 31, 2321 (1983); Endo, M. et al: Pure & Appl. Chem., 58, 387 (1986)).

In the above formula (I), the compound having an X¹ of a bromine atom is hymenialdisine, while the compound having an X¹ of a hydrogen atom is debromohymenialdisine. These compounds have interesting biological activities.

Hymenialdisine and debromohymenialdisine are known to have antineoplastic activities (Pettit, G. et al: Can. J. Chem., 68, 1621 (1990)). Furthermore, debromohymenialdisine is known to have α -adrenoceptor blocking effect (Kobayashi, J. et al: Experimentia., 44, 86 (1988)).

Recently, it has been shown that hymenialdisine and debromohymenialdisine have an inhibitory action against protein phosphokinases, in particular, protein kinase C (Nishizuka, Y.: Nature, 334, 661 (1988); idem, JAMA, 262, 1826 (1989)), which plays an important role in cellular signal transduction (Nambi, P. et al: International Disclosure W093/16703). They are expected to have applications as drugs for the alleviation and treatment of conditions believed to involve the activation of protein kinase C, for example, cerebral ischemic disorders, cerebral vasospasm, ischemic cardiac diseases, high blood pressure, arteriosclerosis, inflammation, asthma, kidney disorders, rheumatoid arthritis, and sthenia of immunofunctions.

Hymenialdisine and debromohymenialdisine, however, can only be obtained in minute quantities when extracted and isolated from nature, so there has been a strong demand for the development of an efficient process of production enabling economical mass production of hymenialdisine and its derivatives. Such a technique, however, has not yet been known. There has just been a


few studies on conversion from aldisin. Even these have not given satisfactory results. Complete synthesis is not yet achieved (Prager, R. et al: Aust. J. Chem., 43, 367 (1990); idem, ibid. 45, 1771 (1992)).

DISCLOSURE OF THE INVENTION

In view of the above situation, the objective of the present invention is to provide a process for economically and efficiently producing of hymenialdisine and its derivatives at a mass production.

The other objectives of the present invention are to provide synthetic intermediates useful for the production of these compounds and a process for producing the same.

The present inventors succeeded in the complete chemical synthesis of hymenialdisine and its derivatives having the formula (I):



(wherein X¹ is a halogen atom or hydrogen atom.)

BEST MODE FOR CARRYING OUT THE INVENTION

It should be noted that natural substances such as hymenialdisine have Z-configuration at the double bond of the 4-position of the pyrrolo[2,3-c]azepine skeleton.

However, according to the present invention, the resultant hymenialdisine and its derivatives are surprisingly obtained only in the Z-configuration form. The halogen atom referred to in the present invention includes a chlorine atom, bromine atom, and iodine atom.

The hymenialdisine having the formula (I) and its derivatives can be synthesized by the processes shown

below. These processes will be explained one after the other.

5 First, in the following process steps 1 and 2, the compounds (IIa) and (IIb) are obtained from the known starting materials (VIII) and (XV), then the compound (IV) is obtained from these compounds (II) (step 3). The compound (V) is obtained from the compound (IV) (step 4), then the compound (VIa) is obtained from the compound (V) (step 5). Further, the compound (VIb) is obtained from 10 the compound (IVa) (step 6) and the compound (VII) is obtained from the compound (VI) (step 7). The desired compound (I) is obtained from the resultant compound (VII) (step 8).

Step 1:

15 The compound (IIa) having an X¹ in formula (II) of a halogen atom can be synthesized from the known starting material pyrrole-2-carboxylic acid or its derivatives (VIII) by the following steps:



35

butyldiphenylsiloxymethyl group, R³ is a trimethylsilyl-ethoxymethyl group, benzyloxymethyl group, p-methoxybenzyloxymethyl group, tert-butyldimethylsiloxy-methyl group, dimethylhexylsiloxymethyl group, or tert-butyldiphenylsiloxymethyl group, either one of X² and X³ is a halogen atom and the other is a hydrogen atom, and W is a hydroxyl group or group which can be easily replaced by an amino group.)

In the above reaction, it is possible to produce the compound of the formula (X) by reacting the pyrrole-2-carboxylic acid having the formula (VIII) or its derivatives with the β -amino acid having the formula (IX) or its derivatives or their organic or inorganic salts.

The groups which can be easily replaced by an amino group for the group W of the compound (VIII) include a halogen atom, carboxylic acid residue, etc. Further, at the group R' of the compound (IX), as the protective group of the carboxyl group, a lower alkyl group preferably having 1 to 6 carbon atoms, particularly preferably 1 to 4 carbon atoms, such as a methyl group, ethyl group, propyl group, isopropyl group, n-butyl group, isobutyl group, or t-butyl group; aralkyl group of 7 to 20 carbon atoms such as a benzyl group or 9-anthrylmethyl group, and also the generally used protective groups described in "Protective Groups in Organic Synthesis" (T.W. Greene; John Wiley & Sons), etc. may be used.

Further, for the synthesis of the compound (X), the various methods described in the "Compendium for Organic Synthesis" (Wiley-Interscience; A Division of John Wiley & Sons) can be used. One example thereof is a method for treating pyrrole-2-carboxylic acid (W = OH in compound (VIII)) in the presence of an organic or inorganic base, and if necessary, by diethyl phosphate cyanide (DEPC), diphenyl phosphate azide (DPPA), dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, 2-iodo-1-methylpyridinium iodide, etc. a method for converting 2-pyrrolecarboxylic acid by an

ordinary method to an acid halide, a symmetric acid anhydride, a mixed acid anhydride, a p-nitrophenyl ester, or other active ester, followed by causing a reaction, etc. may be used.

5 Next, the resultant compound (X) is converted to (XI) by a halogenation reaction. This halogenation reaction may be performed by treating the compound (X) in an inert solvent such as methylene chloride, 1,2-dichloroethane, chloroform, acetonitrile, tetrahydrofuran, 10 dioxane, ethylene glycol dimethyl ether, or dimethyl formamide at a temperature of -50 to 100°C, preferably -10 to 60°C with 0.3 to 1.2 equivalents of a halogenation agent such as N-chlorosuccinimide, trichloroisocyanuric acid, tert-butyl hypochlorite, iodine trichloride, N- 15 bromosuccinimide, bromine, dioxane-bromine complex, 2,4,6,6-tetrabromo-2,5-cyclohexadiene, N-iodosuccinimide, iodine, iodine/potassium iodide, iodine/periodic acid, iodine-morpholine complex, iodine monochloride, or iodine monochloride/zinc chloride for 1 to 12 hours.


20 The resultant compound (XI) is treated, if necessary, by the action of an acid or base or by a suitable means such as catalytic reduction to remove the protective groups, then is subjected to a cyclization reaction. The cyclization reaction is performed by 25 treating the compound (XI) with an organic acid such as methanesulfonic acid or an inorganic acid such as sulfuric acid or polyphosphoric acid or by a mixture thereof with phosphorus pentaoxide at room temperature to 170°C, preferably 80 to 130°C. In this case, if necessary, a 30 solvent which is not interfering with the reaction may be added.

 The resultant compound (XII) may be converted into the compound (XIII) by treatment in an inert solvent such as dimethylformamide, dimethylsulfoxide, 35 tetrahydrofuran, ethylene glycol dimethyl ether, dioxane, benzene, toluene, or xylene in the presence of a base such as sodium hydroxide, potassium hydroxide, or potassium

tert-butoxide at a temperature of -50 to 100°C, preferably -20 to 60°C, with 0.8 to 1.5 equivalents, with respect to compound (XII), of trimethylsilylethoxymethyl chloride, benzyloxymethyl chloride, p-methoxybenzyloxymethyl chloride (Kozikowski, A. et al: Tetrahedron Lett., 28, 5125 (1987)), tert-butyldimethylsiloxyethyl chloride, dimethylhexylsiloxyethyl chloride, or tert-butyldiphenylsiloxyethyl chloride (Benneche, T. et al; Acta Chem. Scan., 43, 706 (1989)) for 1 to 12 hours.

10 The resultant compound (XIII) may be converted into the compound (XIV) by treatment in an inert solvent such as dimethylformamide, dimethylsulfoxide, tetrahydrofuran, ethylene glycol dimethyl ether, dioxane, benzene, toluene, or xylene at a temperature of -50 to 15 100°C, preferably -20 to 60°C, in the presence of a base such as sodium hydroxide, potassium hydroxide, or potassium tert-butoxide, with 0.8 to 1.5 equivalents of trimethylsilylethoxymethyl chloride, benzyloxymethyl chloride, p-methoxybenzyloxymethyl chloride, 20 chloromethylmethyl ether, 2-methoxyethoxymethyl chloride, tert-butoxymethyl chloride, p-anisylloxymethyl chloride, guaiacolmethyl chloride, tert-butyldimethylsiloxyethyl chloride, dimethylhexylsiloxyethyl chloride, or tert-butyldiphenylsiloxyethyl chloride ("Protective Groups in 25 Organic Synthesis" (T.W. Greene; John Wiley & Sons)) for 1 to 12 hours.

 The resultant compound (XIV) is separated and purified by a purification method generally used, for example, column chromatography, to obtain the compound 30 having the formula (IIa):



(wherein R^2 and R^1 are as defined above and X^1 is a halogen atom.)


Note that by separating from the mixture (XIII) the compound having an X^2 of a halogen atom and an X^3 of a hydrogen atom and using it for the next process, it is also possible to obtain the compound of the formula (IIa).

Further, when obtaining a compound (XIV) where the substituents R^2 and R^3 are identical, it is possible to protect the 1-position and the 7-position by a single process by the method similar to the process for producing the compound (XIII) from the compound (XII).

The compounds obtained by these reactions may be used as they are for the next processes, but if necessary, they may also be used after purification by a purification method generally used, for example, recrystallization or column chromatography.

Step 2:

It is possible to synthesize the compound (IIb) having an X^1 in the formula (II) of a hydrogen atom from the known starting material aldisin (XV):



(wherein R^2 and R^1 are as defined above.)


The starting aldisin (XV) is a known compound described in Prager, R. et al: Aust. J. Chem., 43, p. 355 to 365 (1990). It may be prepared in the same way as the method for obtaining the compound (XIV) from the compound

(XII) of the step 1.

The resultant compound (IIb) may be used as is for the next step, but if necessary, it may also be used after purification by a purification method generally used, for example, recrystallization or column chromatography.

Step 3:

It is possible to obtain the compound having the formula (IV) by causing a dialkyl phosphonoacetic acid ester (III) to react with the compound of the formula (II) obtained in the Step 1 or 2:



(wherein R^2 , R^3 , and X^1 are as defined above, R' is a substitutable alkyl group of 1 to 4 carbon atoms, R^1 is an alkyl group having 1 to 4 carbon atoms and the dotted line indicates a single bond existing at one or the other position.)


This step may be performed by causing a reaction in an inert solvent such as tetrahydrofuran, dioxane, ethylene glycol dimethyl ether, benzene, toluene, xylene, or dimethylformamide in the presence of a base such as sodium hydroxide, potassium hydroxide, sodium methoxide, sodium ethylate, or potassium tert-butoxide at a temperature of 0 to 120°C, preferably room temperature to 70°C, with 1 to 10 equivalents, with respect to compound (II), of trimethyl phosphonoacetate,

methyldiethyl phosphonoacetate, ethyldimethyl phosphonoacetate, methyldiisopropyl phosphonoacetate, ethyldiethyl phosphonoacetate, isopropyldiethyl phosphonoacetate, tert-butyldiethyl phosphonoacetate, methyl bis(2,2,2-trifluoroethyl) phosphonoacetate, and other dialkyl phosphonoacetic acid esters for 3 to 36 hours.

The compound (IV) obtained by the above method can be used as it is as a material for producing the compound (V), but when necessary it is possible to separate the compound (IVa) used in the step 6 by column chromatography for example, purify it, and then use that.

Step 4:

It is possible to obtain the compound of the formula (V) by oxidizing the compound of the formula (IV) obtained in the step 3:



(wherein R¹, R², R³, and X¹ are as defined above and the dotted lines show a single bond present at either one of the positions.)


This step may be performed by causing a reaction in an inert solvent such as tetrahydrofuran, diethyl ether, diethylene glycol dimethyl ether, or toluene in the presence of a strong base such as potassium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide, lithium bis(trimethylsilyl)amide, or lithium diisopropylamide, at a temperature of -100 to 20°C, preferably -78 to 0°C, with 1 to 1.5 equivalents, with

respect to compound (IV), of an oxidizing agent such as 2-benzenesulfonyl-3-phenyloxaziridine (Davis, F. et al: J. Org. Chem., 53, 2087 (1988)), oxodiperoxymolybdenum (pyridine)(hexamethylphosphoric triamide) complex (Vedejs, E. et al: J. Org. Chem., 43, 188 (1978)), or molecular oxygen (Wasserman, H. et al: Tetrahedron Lett., 1731 (1975)) for 1 to 12 hours.

The compound (V) obtained by the above method may be used as it is as the material for producing the compound (VIa), but if necessary, it may also be used after purification by a purification method generally used, for example, column chromatography.

Step 5:

It is possible to obtain the compound having the formula (VIa) by sulfonylizing the hydroxyl group of the compound (V) obtained in the step 4:



(wherein R^1 , R^2 , R^3 , and X^1 are as defined above, R^4 is an alkylsulfonyloxy group or arylsulfonyloxy group, preferably the alkyl group includes an alkyl group having 1 to 4 carbon atoms or a halogen substituted methyl group, preferably, as the halogen, a fluorine atom or chlorine atom, preferably the aryl group includes a phenyl group, p-tolyl group, 4-methoxyphenyl group, 4-chlorophenyl group, or nitrophenyl group.)

This step may be performed by causing a reaction in an inert solvent such as methylene chloride, 1,2-dichloroethane, chloroform, carbon tetrachloride, acetonitrile, diethyl ether, tetrahydrofuran, dioxane,


benzene, toluene, xylene, or ethyl acetate in the presence of a base such as triethylamine, diisopropylethylamine, pyridine, sodium carbonate, sodium hydrogen carbonate, potassium carbonate or potassium hydrogencarbonate at a temperature of -20 to 100°C, preferably -10 to 60°C, with 1 to 10 equivalents, with respect to compound (V), of a sulfonylating agent such as methanesulfonyl chloride, methanesulfonic anhydride, ethanesulfonyl chloride, 1-propanesulfonyl chloride, 1-buthanesulfonyl chloride, trifluoromethanesulfonyl chloride, trifluoromethanesulfonic anhydride, trichloromethanesulfonyl chloride, α -toluenesulfonyl chloride, benzenesulfonyl chloride, p-toluenesulfonyl chloride, p-toluenesulfonic anhydride, 4-methoxybenzenesulfonyl chloride, 4-chlorobenzenesulfonyl chloride, 2-nitrobenzenesulfonyl chloride, 3-nitrobenzenesulfonyl chloride, or 4-nitrobenzenesulfonyl chloride for 30 minutes to 12 hours.

The compound (VIa) obtained by the above method may be used as it is, as the material for producing the compound (VII), but if necessary, it may also be used after purification by a purification method generally used, for example, column chromatography.

Step 6:

It is possible to obtain the compound having the formula (VIb) where in the formula (VI) the R^6 is a halogen atom by halogenating the compound having the formula (IVa) obtained by separation of the compound (IV) obtained in the step 3:






10 (wherein R¹, R², R³, and X¹ are as defined above and R⁵ is a halogen atom.)

This step may be performed by treating the compound (IVa) in an inert solvent such as methylene chloride, 1,2-dichloroethane, chloroform, acetonitrile, tetrahydrofuran, dioxane, ethylene glycol dimethyl ether, or dimethylformamide at -50 to 120°C, preferably -20 to 80°C, with 0.3 to 1.2 equivalents of a halogenating agent such as N-chlorosuccinimide, trichloroisocyanuric acid, tert-butyl hypochlorite, iodine trichloride, N-bromosuccinimide, bromine, dioxane-bromine complex, 2,4,6,6-tetrabromo-2,5-cyclohexadiene, N-iodosuccinimide, iodine, iodine/potassium iodide, iodine/periodic acid, iodine-morpholine complex, iodine monochloride, or iodine monochloride zinc chloride for 1 to 12 hours.

25 The compound (Vib) obtained by the above method may be used as it is, as the material for producing the compound (VII), but if necessary, it may also be used after purification by a purification method generally used, for example, column chromatography.

30 Step 7:

It is possible to obtain the compound having the formula (VII) by reacting the compound having the formula (VI) obtained in step 5 or 6 with guanidine.



(wherein R¹, R², R³, and X¹ are as defined above, and R⁶ is an alkylsulfonyloxy group, arylsulfonyloxy group, or halogen atom.)

This step may be performed by causing a reaction with the compound (VI) in an inert solvent such as benzene, toluene, xylene, tetrahydrofuran, dioxane, ethylene glycol methyl ether, dimethylformamide, or dimethylsulfoxide at a temperature of 0 to 200°C, preferably room temperature to 120°C, with 1 to 10 equivalents of guanidine for 2 to 24 hours.


The compound (VII) obtained by the above method may be used as it is, as the material for producing the compound (I), but if necessary it may also be used after purification by a purification method generally used, for example, recrystallization or column chromatography.

Regarding the configuration of double bond portion of the 4-position of the compound (VII), the Z-configuration was confirmed, for example, from the fact that the signal of the 5-position methylene proton in proton NMR shifts to the low magnetic field side due to anisotropic effect of the spatially close carbonyl group. Further, this result can be confirmed from the conversion of the compound (VII) to the compound (I).

Step 8:

It is possible to obtain the compound having the formula (I) by removing the protection of the compound

having the formula (VII) obtained in the step 7:



(wherein R², R³, and X¹ are as defined above.)

15 This step may be performed by causing a reaction at a temperature of -50 to 150°C, preferably -20 to 120°C, of the compound (VII) with 1 to 10 equivalents of tetrabutylammonium fluoride/tetrahydrofuran, 1 to 10 equivalents of tetrabutylammonium fluoride/ethylenediamine, 1 to 10 equivalents of methanol/hydrochloric acid, 1 to 10 equivalents of ethanol/hydrochloric acid, etc. or by
20 treatment with 1 to 10 equivalents of boron trifluoride ether complex, 1 to 10 equivalents of trifluoroacetic acid, catalytic reduction (Pd-C, hydrogen, 1 atm), etc., then treatment with 5 to 20 equivalents of
25 benzyltrimethylammonium hydroxide, 5 to 20 equivalents of triethylamine, etc., or oxidation by 1 to 10 equivalents of 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ).

30 Further, this step may be performed by general de-protection methods such as a method of using an acid catalyst, the catalytic reduction method, and oxidation, for example, the various methods as described in "Protective Groups in Organic Synthesis" (T.W. Greene; John Wiley & Sons), etc.

35 The compound (I) obtained by the above method may be purified by a purification method generally used, for example, recrystallization or column chromatography.

Note that the compound (I) may be obtained as a

pharmaceutically acceptable salt according to an ordinary method, for example, an acid addition salt of the compound having the formula (I) may be produced by reacting the same by an ordinary method with an inorganic acid such as

5 hydrochloric acid, nitric acid, sulfuric acid, hydrobromic acid, or phosphoric acid or an organic acid such as maleic acid, fumaric acid, tartaric acid, citric acid, lactic acid, oxalic acid, acetic acid, benzoic acid, methanesulfonic acid, p-toluenesulfonic acid, adipic acid,

10 palmitic acid, and tannic acid.

EXAMPLES

The present invention will now be further illustrated by, but is by no means limited to, the following Reference Examples and Examples.

15 Reference Example 1: Synthesis of methyl 3-(pyrrol-2-ylcarbonylamino)propionate (1)

i) A 0.2 ml amount of dimethylformamide and 19.6 ml of thionyl chloride were dropwise added under room temperature to a 100 ml toluene suspension of 20 g of

20 pyrrole-2-carboxylic acid. The mixture was stirred at 60°C for 2 hours, then the solvent was distilled off under reduced pressure and the residue was dried under reduced pressure to obtain crude crystals of pyrrole-2-carbonyl chloride.

25 ii) A 76.6 ml amount of trimethylamine was gradually dropwise added under ice cooling to a 100 ml methylene chloride suspension of 30.7 g of β -alaninemethylester hydrochloride. The mixture was stirred at room temperature for 1 hour. Then, a 200 ml methylene

30 chloride solution of pyrrole-2-carbonyl chloride obtained in the above process i) was gradually dropwise added under ice cooling. The mixture was stirred at room temperature for 3 hours. A 200 ml amount of water was added to the reaction solution, the mixture was stirred, then the

35 methylene chloride layer was removed and washed

by 200 ml of 5% hydrochloric acid, then 250 ml of a saturated aqueous solution of sodium hydrogen carbonate. The organic layer was dried, filtered, and then concentrated under reduced pressure to obtain crude crystals which were then recrystallized from methylene chloride/methanol to obtain 22 g of the above-referenced compound (1) (yield 62%).

5
10 Reference Example 2: Synthesis of methyl 3-(2-bromopyrrol-5-ylcarbonylamino)propionate and methyl 3-(3-bromopyrrol-5-ylcarbonylamino)propionate (2)

A 907 mg amount of N-bromosuccinimide was added under ice cooling to an 18 ml tetrahydrofuran solution of 1 g of the compound (1) synthesized in Reference Example 1. The mixture was stirred under ice cooling for 2 hours, then under room temperature for a further 2 hours. The solvent was distilled off under reduced pressure, then the residue was purified by silica gel column chromatography (hexane: ethyl acetate = 3:1) to obtain 0.975 g of a mixture of the above-referenced compounds (2) (yield 70%).

20 Reference Example 3: Synthesis of 3-(2-bromopyrrol-5-ylcarbonylamino)propionic acid and 3-(3-bromopyrrol-5-ylcarbonylamino)propionic acid (3)

A 25 ml amount of a 10% aqueous solution of potassium hydroxide was dropwise added under ice cooling to a 20 ml dioxane solution of 1.6 g of the mixture of the compounds (2) synthesized in Reference Example 2. The mixture was stirred at room temperature for 3 hours, then the reaction solution was adjusted by concentrated hydrochloric acid to a pH of 3 under ice cooling and extraction was performed by ethyl acetate. The extract was dried, filtered, then concentrated under reduced pressure to obtain crude crystals which were then recrystallized from isopropyl ether to obtain 1.3 g of a mixture of the above-referenced compounds (3) (yield 86%).

35 Reference Example 4: Synthesis of 2-bromo-6,7-

dihydropyrrolo[2,3-c]azepin-4,8(1H,5H)dione and 3-bromo-6,7-dihydropyrrolo[2,3-c]azepin-4,8(1H,5H)dione (4)

A 0.1 g amount of phosphorus pentaoxide was added to 15 g of polyphosphoric acid, then was stirred at 120°C for 1 hour. The temperature was lowered once to 100°C, then 3 g of the mixture of the compounds (3) synthesized in Reference Example 3 was added. The mixture was stirred at 100°C for 1 hour, then the reaction mixture was cooled to room temperature. Ice was added to the reaction mixture under ice cooling, then a 10% aqueous solution of sodium hydroxide was used to adjust the pH to 5. Extraction was performed by ethyl acetate, then the extract was dried, filtered, and concentrated under reduced pressure to obtain 1.9 g of the mixture of the above-referenced compounds (4) (yield 68%).

Reference Example 5: Synthesis of 2-bromo-1-trimethylsilylethoxymethyl-6,7-dihydropyrrolo[2,3-c]azepin-4,8(1H,5H)dione (5) and 3-bromo-1-trimethylsilylethoxymethyl-6,7-dihydropyrrolo[2,3-c]azepin-4,8(1H,5H)-dione (6)

A 5 g amount of the mixture of the compounds (4) synthesized in Reference Example 4 was gradually added under ice cooling to a 100 ml dimethylformamide suspension of 0.87 g of sodium hydride (60% oil). The mixture was stirred at room temperature for 1 hour. A 3.7 ml amount of trimethylsilylethoxymethyl chloride was dropwise added under ice cooling, the mixture was stirred at room temperature for 2 hours, then a saturated aqueous solution of ammonium chloride was added and extraction was performed by ethyl acetate. The extract was washed with saturated saline, dried, filtered, and concentrated under reduced pressure to obtain a mixture of the above-referenced compounds which were then separated and purified by silica gel column chromatography (hexane:ethyl acetate = 4:1 to 2:1) to obtain 2.7 g of the above-referenced compound (5) (yield 35%) and 1.8 g of the above-referenced compound (6) (yield 23%).

Further, the crude crystals of the above-referenced compounds (5) and (6) were recrystallized from hexane/ether to obtain 2.2 g of purified crystals of (5) and 1.4 g of purified crystals of (6), respectively.

5 Reference Example 6: Synthesis of 2-bromo-1,7-
di(trimethylsilylethoxymethyl)-6,7-dihydropyrrolo[2,3-
c]azepin-4,8(1H,5H)dione (7)

10 A 5 ml dimethylformamide solution of 740 mg of
the compound (5) synthesized in Reference Example 5 was
dropwise added under ice cooling to a 10 ml
dimethylformamide suspension of 87.3 mg of sodium hydride
(60% oil). The mixture was stirred at room temperature for
1 hour. A 0.39 ml amount of trimethylsilylethoxymethyl
chloride was dropwise added under ice cooling, the mixture
15 was stirred at room temperature for 2 hours, then a
saturated aqueous solution of ammonium chloride was added
and extraction was performed by ethyl acetate. The extract
was washed with saturated saline, dried, filtered, and
concentrated under reduced pressure to obtain a residue
20 which was purified by silica gel column chromatography
(hexane:ether - 2:1) to obtain 450 mg of the above-
referenced compound (7) (yield 45%).

25 Reference Example 7: Synthesis of 1,7-
di(trimethylsilylethoxymethyl)-6,7-dihydropyrrolo[2,3-
c]azepin-4,8(1H,5H)dione (8)

30 A 500 mg amount of the 6,7-dihydropyrrolo[2,3-
c]azepin-4,8(1H,5H)dione (aldisin) described in the
reference (Prager, R. et al: Aust. J. Chem., 43, p. 355-
365 (1990)) was added to a 20 ml dimethylformamide
suspension of 252 mg of sodium hydride (60% oil). The
mixture was stirred at room temperature for 1 hour. A 1.12
ml amount of trimethylsilylethoxymethyl chloride was added
under ice cooling, the mixture was stirred at room
temperature for 3 hours, then a saturated aqueous solution
35 of ammonium chloride was added and extraction was performed
by ethyl acetate. The extract was washed

with saturated saline, dried, filtered, and concentrated under reduced pressure to obtain a residue which was purified by silica gel column chromatography (hexane:ethyl acetate = 6:1) to obtain 623 mg of the above-referenced compound (8) (yield 48%).

5 Example 1: Synthesis of 2-bromo-4-ethoxycarbonylylidene-1,7-di(trimethylsilylethoxymethyl)-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one (9) and 2-bromo-4-ethoxycarbonylmethyl-1,7-di(trimethylsilyl-
10 ethoxymethyl)-6,7-dihydropyrrolo[2,3-c]azepin-8-one (10)

 A 0.86 ml amount of ethyl diethyl phosphonoacetate was dropwise added under ice cooling to a 4 ml ethylene glycol dimethyl ether suspension of 173 mg of sodium hydride (60% oil). The mixture was stirred at room
15 temperature for 1 hour, then a 3 ml ethylene glycol dimethyl ether solution of 435 mg of the compound (7) synthesized in Reference Example 6 was dropwise added and the mixture was stirred at 50°C for 24 hours. A saturated aqueous solution of ammonium chloride was added and
20 extraction was performed with ether. The extract was washed with saturated saline, dried, filtered, and concentrated under reduced pressure to obtain the above-referenced compound which was then separated and purified by silica gel column chromatography (hexane:ether = 2:1) to
25 obtain 107 mg of the above-referenced compound (9) (yield 22%) and 304 mg of the above-referenced compound (10) (yield 61%).

Example 2: Synthesis of 4-ethoxycarbonylylidene-1,7-di(trimethylsilylethoxymethyl)-4,5,6,7-tetrahydro-
30 pyrrol[2,3-c]azepin-8-one (11) and 4-ethoxycarbonyl-methyl-
 1,7-di(trimethylsilylethoxymethyl)-6,7-dihydropyrrolo[2,3-c]azepin-8-one (12)



The same procedure was followed as in Example 1
to obtain 205 mg of the above-referenced compound (11)
(yield 25%) and 470 mg of the above-referenced compound
(12) (yield 58%) from 700 mg of the compound (8)
5 synthesized in Reference Example 7, 329 mg of sodium

7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2206
2207
2208
2209
2210
2211
2212
2213
2214
2215
2216
2217
2218
2219
222

hydride (60% oil), and 1.63 ml of ethyl diethyl phosphonoacetate.

Example 3: Synthesis of 2-bromo-4-ethoxy-carbonylhydroxymethyl-1,7-(trimethylsilylethoxymethyl)-6,7-dihydropyrrolo[2,3-c]azepin-8-one (13)

5 A 394 mg amount of a mixture of the compounds (9) and (10) synthesized in Example 1 was dissolved in 8 ml of tetrahydrofuran, then 1.51 ml of potassium bis(trimethylsilyl)amide (0.5 mole/toluene solution) was
10 gradually dropwise added at -78°C. The mixture was stirred at the same temperature for 20 minutes, then 198 mg of 2-benzenesulfonyl-3-phenyloxaziridine (Davis, F. et al: J. Org. Chem., 53, 2087 (1988)) was added and the
15 resultant mixture was stirred for a further 3 hours. A saturated aqueous solution of ammonium chloride was added and extraction was performed with ether. The extract was washed with saturated saline, dried, filtered, and concentrated under reduced pressure to obtain a residue
20 which was then purified by silica gel column chromatography (hexane:ether = 3:2) to obtain 315 mg of the above-referenced compound (13) (yield 78%).

Example 4: Synthesis of 4-ethoxycarbonylhydroxymethyl-1,7-di(trimethylsilylethoxymethyl)-6,7-dihydropyrrolo[2,3-c]azepin-8-one (14)

25 A 135 mg amount of the above-referenced compound (14) (yield 72%) was obtained from 182 mg of a mixture of the compound (11) and (12) synthesized in Example 2, 0.88 ml of potassium bis(trimethylsilyl)amide (0.5 mol/toluene solution), and 106 mg of 2-benzenesulfonyl-3-phenyloxaziridine, in the same manner as in Example 3.

Example 5: Synthesis of 2-bromo-4-ethoxycarbonyl(methanesulfonyloxy)methyl-1,7-di(trimethylsilylethoxymethyl)-6,7-dihydropyrrolo[2,3-c]azepin-8-one (15)

35 A 0.046 ml amount of methanesulfonyl chloride was dropwise added under ice cooling to a 5 ml methylene chloride solution of 295 mg of the compound (13)

synthesized in Example 3 and 0.21 ml of triethylamine. The mixture was stirred at room temperature for 1 hour. A saturated aqueous solution of sodium hydrogen carbonate was added thereto and extraction was performed with methylene chloride. The extract was washed with saturated saline, dried, filtered, and concentrated under reduced pressure to obtain a residue which was then purified by silica gel column chromatography (hexane:ether = 2:3) to obtain 331 mg of the above-referenced compound (15) (yield 99%).

Example 6: Synthesis of 4-ethoxycarbonyl (methanesulfonyloxy)methyl-1,7-di(trimethylsilyl)-ethoxymethyl)-6,7-dihydropyrrolo[2,3-c]azepin-8-one (16)

A 940 mg amount of the above-referenced compound (16) (yield 97%) was obtained from 840 mg of the compound (14) synthesized in Example 4, 0.69 ml of triethylamine, and 0.15 ml of methanesulfonyl chloride, in the same manner as in Example 5.

Example 7: Synthesis of 4-ethoxycarbonylbromomethyl-1,7-di(trimethylsilylethoxymethyl)-6,7-dihydropyrrolo[2,3-c]azepin-8-one (17)

A 39 mg amount of N-bromosuccinimide was added under ice cooling to a 2 ml tetrahydrofuran solution of 99 mg of the compound (11) synthesized in Example 2. The mixture was stirred at room temperature for 5 hours. The solvent was distilled off under reduced pressure to obtain a residue which was then purified by silica gel column chromatography (hexane:ether = 2:1) to obtain 69 mg of the above-referenced compound (17) (yield 60%).

Example 8: Synthesis of 4-(2-amino-4-oxo-2-imidazolin-5-ylidene)-2-bromo-1,7-di(trimethylsilylethoxymethyl)-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one (18)

A 5 ml dimethylformamide solution of 325 mg of the compound (15) synthesized in Example 5 and 143 ml of guanidine was stirred at 50°C for 6 hours. The solvent was distilled off under reduced pressure to obtain a

residue which was then purified by silica gel column chromatography (methylene chloride:methanol = 15:1). The solvent was distilled off under reduced pressure, then the crude crystals were recrystallized from hexane/ether to obtain 120 mg of the above-referenced compound (18) (yield 42%).

5
10 Example 9: Synthesis of 4-(2-amino-4-oxy-2-imidazolin-5-ylidene)-1,7-di(trimethylsilyl-ethoxymethyl)-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one (19)

A 420 mg amount of the above-referenced compound (19) was obtained from 935 mg of the compound (16) synthesized in Example 6 and 281 mg of guanidine to obtain the crude crystals in the same manner as in Example 8 followed by, recrystallizing from ether/methanol (yield 50%).

15
20 Example 10: Synthesis of 4-(2-amino-4-oxy-2-imidazolin-5-ylidene)-2-bromo-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one (hymenialdisine) hydrochloride (20)

A 3 ml amount of 10% hydrochloric acid was added to a 3 ml methanol solution of 300 mg of the compound (18) synthesized in Example 8. The mixture was stirred at 90°C for 1 hour. The solvent was distilled off under reduced pressure to obtain a residue which was then purified by silica gel column chromatography (chloroform:methanol:2% acetic acid = 65:35:10). The solvent was distilled off under reduced pressure, then the residue was treated by 1 ml of isopropyl alcohol saturated with hydrochloric acid to give the crude crystals which were recrystallized by methanol/ether to obtain 150 mg of the above-referenced compound (20) (yield 81%).

25
30
35 Example 11: Synthesis of 4-(2-amino-4-oxy-2-imidazolin-5-ylidene)-4,5,6,7-tetrahydropyrrolo[2,3-c]azepin-8-one (debromohymenialdisine) hydrochloride (21)

A 0.5 ml amount of trifluoroacetic acid was dropwise added under ice cooling to a 3.5 ml methylene chloride

solution of 105 mg of the compound (19) synthesized in Example 9. The mixture was stirred at room temperature for 20 minutes. The solvent was distilled off under reduced pressure, then the residue was dissolved in 5 ml of 50% acetic acid/0.05 ml of concentrated hydrochloric acid and stirred at 90°C for 1 hour. The solvent was again distilled off under reduced pressure, then the residue was dissolved in 5 ml of methanol/1 ml of triethyl amine and the resultant mixture was stirred at 100°C for 3 hours. The solvent was distilled off under reduced pressure, then the residue was purified by the same procedure as in Example 10 to obtain 42 mg of the above-referenced compound (21) (yield 75%).

The physicochemical data of the compounds obtained in the above Reference Examples is shown in Table 1 and the physicochemical data of the compounds obtained in the Examples of the present invention is shown in Table 2.

Table 1 : Reference Examples

Compound No.	Chemical structure	Properties m. p.	IR	NMR
1		Colorless crystals m. p. 129-130°C	(CHCl ₃) 3453, 1734, 1640, 1558, 1516, 1439, 1316	¹ H-NMR (CDCl ₃) 2.63(2H, t), 3.68(2H, t), 3.71(3H, s), 6.23(1H, dd), 6.5(1H, brs), 6.58(1H, m), 6.92(1H, m), 9.4(1H, brs)
2		Colorless crystals	(CHCl ₃) 3444, 1728, 1648, 1558, 1516, 1439, 1045, 926	¹ H-NMR (CDCl ₃) 2.62 and 2.64 (total 2H, each t), 3.66(2H, t), 3.71 and 3.72 (total 3H, each s), 6.16 and 6.54 (total 1H, each d), 6.49 and 6.9 (total 1H, d and dd), 6.48 and 6.55 (total 1H, each brs), 9.38 and 10.35 (total 1H, each brs)
3		Colorless crystals	(KBr) 3454, 3164, 2957, 1712, 1612, 1570, 1516, 1434, 1406, 1324, 1220, 1045	¹ H-NMR (d ₂ -DMSO) 2.47(2H, t), 3.4(2H, t), 6.11 and 6.82 (total 1H, each d), 6.72 and 6.97 (total 1H, d and dd), 8.05 and 8.16 (total 1H, each t)
4		Colorless crystals	(KBr) 3347, 3460, 1667, 1645, 1546, 1460, 1365, 1258, 892	¹ H-NMR (d ₂ -DMSO) 2.7(2H, m), 3.35(2H, m), 6.55 and 7.18 (total 1H, s and d), 8.37 and 8.44 (total 1H, both m), 12.5 and 12.9 (total 1H, both brs)

Table 1 : Reference Examples (Continued)

Compound No.	Chemical structure	Properties m. p.	IR	NMR
5		Colorless crystals m.p. 86-87°C	(CHCl ₃) 3418, 1658, 1526, 1464, 1251, 1086, 838	¹ H-NMR (CDCl ₃) -0.038 (9H, s), 0.89 (2H, t), 2.84 (2H, m), 3.5-3.6 (4H, m), 5.9 (2H, s), 6.79 (1H, s), 6.86 (1H, m)
6		Colorless crystals m.p. 72-73°C	(CHCl ₃) 3416, 1660, 1478, 1483, 1251, 1096, 838	¹ H-NMR (CDCl ₃) -0.01 (9H, s), 0.93 (2H, t), 2.86 (2H, m), 3.49-3.61 (4H, m), 5.89 (2H, s), 6.6 (1H, m), 7.15 (1H, s)
7		A colorless oil	(CHCl ₃) 2955, 1644, 1525, 1450, 1251, 1071, 861, 838	¹ H-NMR (CDCl ₃) -0.038 (9H, s), 0.04 (9H, s), 0.88 (2H, t), 0.94 (2H, t), 2.83 (2H, m), 3.55 (2H, t), 3.6 (2H, t), 3.76 (2H, m), 5.03 (2H, s), 5.86 (2H, s), 6.73 (1H, s)
8		Colorless crystals	(CHCl ₃) 3019, 2955, 1640, 1526, 1485, 1251, 1074	¹ H-NMR (CDCl ₃) -0.01 (9H, s), 0.03 (9H, s), 0.92 (2H, t), 0.95 (2H, t), 2.87 (2H, m), 3.57 (2H, t), 3.63 (2H, t), 3.8 (2H, m), 5.05 (2H, s), 5.74 (2H, s), 6.73 (1H, d), 7.07 (1H, d)

Table 2 : Examples.





Compound No.	Chemical structure	Properties	IR	NMR	Mass
9		A colorless oil	(CHCl ₃) 3018, 2955, 1700, 1636, 1612, 1475, 1435, 1224, 1208, 1077, 837	¹ H-NMR (CDCl ₃) -0.04 (9H, s), -0.016 (9H, s), 0.82-0.98 (4H, m), 1.29 (3H, t), 3.37 (2H, m), 3.47-3.64 (6H, m), 4.16 (2H, q), 4.95 (2H, s), 5.76 (2H, s), 6.01 (1H, t), 6.38 (1H, s)	HRFABMS Calcd for C ₂₁ H ₂₄ N ₂ O ₄ Si ₂ Br (Si) ₂ t (LiH) ⁺ : 579.2 C ₂₁ H ₂₄ N ₂ O ₄ Si ₂ Br (Si) ₂ t (LiH) ⁺ : 581.2
10		A colorless oil	(CHCl ₃) 3019, 1732, 1626, 1524, 1505, 1470, 1427, 1250, 1076, 837	¹ H-NMR (CDCl ₃) -0.045 (9H, s), -0.01 (9H, s), 0.89 (4H, m), 1.22 (3H, t), 3.36 (2H, s), 3.73 (2H, d), 4.13 (2H, q), 4.93 (2H, s), 5.84 (2H, s), 5.99 (1H, t), 6.34 (1H, s)	HRFABMS Calcd for C ₂₁ H ₂₄ N ₂ O ₄ Si ₂ Br (Si) ₂ t (LiH) ⁺ : 579.1898 Found : 579.1913 Calcd for C ₂₁ H ₂₄ N ₂ O ₄ Si ₂ Br (Si) ₂ t (LiH) ⁺ : 581.1877 Found : 581.1894
11		A colorless oil	(CHCl ₃) 2954, 1699, 1635, 1608, 1474, 1251, 1179, 1073, 861	¹ H-NMR (CDCl ₃) -0.04 (9H, s), -0.013 (9H, s), 0.83-0.99 (4H, m), 1.29 (3H, t), 3.4 (2H, m), 3.45-3.65 (6H, m), 4.17 (2H, q), 4.95 (2H, s), 5.63 (2H, s), 6.07 (1H, t), 6.34 (1H, d), 6.98 (1H, d)	HRFABMS Calcd for C ₂₁ H ₂₄ N ₂ O ₄ Si ₂ (H) ⁺ 495.2711 Found : 495.2717
12		A colorless oil	(CHCl ₃) 3007, 2954, 1730, 1624, 1486, 1251, 1072, 861	¹ H-NMR (CDCl ₃) -0.04 (9H, s), -0.008 (9H, s), 0.9 (4H, m), 1.21 (3H, t), 3.4 (2H, brs), 3.52 (4H, m), 3.73 (2H, d), 4.13 (2H, q), 4.94 (2H, s), 5.71 (2H, s), 5.95 (1H, t), 6.26 (1H, d), 7.03 (1H, d)	HRFABMS Calcd for C ₂₁ H ₂₄ N ₂ O ₄ Si ₂ (H) ⁺ 495.2711 Found : 495.2734

Table 2 : Examples(Continued)










Compound No.	Chemical structure	Properties	IR	NMR	Mass
13		A colorless oil	(CHCl ₃) 3526, 2954, 1731, 1628, 1469, 1445, 1250, 1079, 860	¹ H-NMR(CDCl ₃) -0.05(9H, s), -0.001(9H, s), 0.83-0.95(4H, m), 1.13(3H, t), 3.29(1H, d), 3.52(4H, m), 3.72(1H, dd), 3.78(1H, dd), 4.17(2H, q), 4.89(1H, d), 4.9(1H, d), 4.96(1H, d), 5.83(2H, s), 6.17(1H, t), 6.47(1H, s)	HRFAB/MS Calcd for C ₂₁ H ₂₇ O ₄ N ₂ Br(Si) ₃ † (LH) ⁺ : 595.1846; Found: 595.1870
14		A colorless oil	(CHCl ₃) 3502, 3014, 1728, 1625, 1467, 1251, 1074, 837	¹ H-NMR(CDCl ₃) -0.05(9H, s), -0.01(9H, s), 0.88(2H, t), 0.92(2H, t), 1.1(3H, t), 3.28(1H, d), 3.5(2H, t), 3.53(2H, t), 3.72(1H, dd), 3.78(1H, dd), 4.62(2H, m), 4.89(1H, d), 4.94(1H, d), 4.97(1H, d), 5.7(2H, s), 6.14(1H, t), 6.39(1H, d), 7.02(1H, d)	HRFAB/MS Calcd for C ₂₁ H ₂₇ O ₄ N ₂ (Si) ₃ † (LH) ⁺ : 597.1826; Found: 597.1854
15		A light yellow oil	(CHCl ₃) 2955, 1755, 1632, 1470, 1446, 1368, 1250, 1176, 1081, 967	¹ H-NMR(CDCl ₃) -0.04(9H, s), -0.006(9H, s), 0.83-0.9(4H, m), 1.15(3H, t), 3.15(3H, s), 3.47-3.59(4H, m), 3.77(2H, d), 4.18(2H, q), 4.87(1H, d), 4.99(1H, d), 5.72(1H, s), 5.76(1H, d), 5.95(1H, s), 6.3(1H, t), 6.49(1H, s)	—
16		A light yellow oil	(CHCl ₃) 3018, 2955, 1755, 1627, 1368, 1250, 1176, 1076, 860	¹ H-NMR(CDCl ₃) -0.037(9H, s), -0.006(9H, s), 0.91(2H, t), 0.95(2H, t), 1.14(3H, t), 3.13(3H, s), 3.45-3.59(4H, m), 3.77(1H, d), 4.18(2H, m), 5.63(1H, d), 5.76(1H, d), 5.78(1H, s), 6.26(1H, t), 6.42(1H, d), 7.05(1H, d)	—

Table 2 : Examples (Continued)


Compound No.	Chemical structure	Physical Properties	IR	NMR	Mass
17		A colorless oil	—	¹ H-NMR (CDCl ₃) -0.035 (9H, s), 0.82-0.9 (4H, m), 3.45-3.6 (4H, m), 4.18 (2H, q), 4.96 (1H, d), 5.25 (1H, s), 5.7 (1H, d), 6.4 (1H, l), 6.48 (1H, s)	—
18		Colorless crystals m.p. 115-117°C	(CHCl ₃) 3444, 3350, 2954, 1690, 1628, 1475, 1439, 1250, 1075, 837	¹ H-NMR (CD ₃ OD) -0.06 (9H, s), 0.86 (2H, l), 3.37 (2H, l), 3.54 (2H, l), 4.95 (2H, s), 6.57 (1H, s)	HRFABMS Calcd for C ₂₁ H ₂₅ N ₃ O ₄ Si ₃ (L ⁺ H ⁺) : 590.1806 ; Found : 590.1830 Calcd for C ₂₁ H ₂₅ N ₃ O ₄ Si ₃ Br (L ⁺ H ⁺) : 592.1786 ; Found : 592.1826
19		Colorless crystals m.p. 125-127°C	(CHCl ₃) 3627, 3436, 3339, 3024, 2954, 1688, 1628, 1476, 1284, 1075, 837	¹ H-NMR (CD ₃ OD) -0.06 (9H, s), 0.86 (2H, l), 3.39 (2H, l), 3.51 (2H, l), 4.98 (2H, s), 6.43 (1H, d), 7.25 (1H, d)	HRFABMS Calcd for C ₂₁ H ₂₅ N ₃ O ₄ Si ₃ Br (L ⁺ H ⁺) : 592.1786 ; Found : 592.1826
20		Yellow crystals m.p. 240-242°C (decomp.)	(KBr) 3400 (br), 3255 (br), 1747, 1708, 1628, 1542, 1483, 1366, 1275, 1175, 1122, 1054	¹ H-NMR (CD ₃ OD) 3.5 (4H, brs), 6.67 (1H, s) ¹³ C-NMR (CD ₃ OD) 32.6, 30.2, 105.7, 111, 120.9, 122.4, 127.6, 130, 154.6, 162.5, 163.7	FABMS C ₂₁ H ₂₅ N ₃ O ₄ Si ₃ Br ⁺ : 324 C ₂₁ H ₂₅ N ₃ O ₄ Si ₃ Br ⁺ : 326
21		Yellow crystals m.p. 235-238°C (decomp.)	(KBr) 3420 (br), 3248 (br), 1748, 1712, 1640, 1538, 1476, 1429, 1359, 1264, 1117, 788	¹ H-NMR (CD ₃ OD) 3.37-3.47 (4H, m), 7.15 (1H, d), 34.1, 41.4, 111.2, 122.3, 123.2, 124.8, 128, 133.4, 155.7, 165, 166.5	HRFABMS Calcd for C ₂₁ H ₂₅ N ₃ O ₄ Si ₃ Br ⁺ : 324 Found : 324.0991 Found : 324.0992

According to the present invention, it is possible to economically and efficiently mass produce hymenialdisine and its derivatives by complete chemical synthesis. Further, it is possible to provide

5 intermediates useful for the production of these compounds.


THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A process for producing hymenialdisine or its derivatives having the formula (I):



(wherein X1 is a halogen atom or a hydrogen atom)
characterized by

reacting a compound having the formula (II):



(wherein R2 is a trimethylsilylethoxymethyl group, benzyloxymethyl group, p-methoxybenzyloxymethyl group, methoxymethyl group, methoxyethoxymethyl group, tert-butoxymethyl group, p-anisylloxymethyl group, guaiacolmethyl group, tert-butyl dimethylsiloxymethyl group, dimethylthexylsiloxymethyl group, or tert-butyl diphenylsiloxymethyl group, R3 is a trimethylsilyl-ethoxymethyl group, benzyloxymethyl group, p-methoxybenzyloxymethyl group, tert-butyl dimethylsiloxymethyl group, dimethylthexylsiloxymethyl group, or tert-butyl diphenylsiloxymethyl group, and X1 is as defined above) with a dialkylphosphonoacetic acid ester having the formula (III):


25

30




(wherein R' is a substitutable alkyl group having 1 to 4 carbon atoms and R¹ is an alkyl group having 1 to 4 carbon atoms)

5 to synthesize a compound having the formula (IV):




(wherein R¹, R², R³, and X¹ are as defined above, and the dotted line indicates a single bond existing at one or the other position)


15 reacting the compound having the formula (IV) with an oxidizing agent to synthesize the compound having the formula (V):




25 (wherein R¹, R², R³, and X¹ are as defined above)
 reacting the compound having the formula (V) with a
 halogenated alkylsulfonyl, halogenated arylsulfonyl,
 alkylsulfonyl acid anhydride, or arylsulfonyl acid
 30 anhydride to synthesize a compound of the formula (VIa):




(wherein R¹, R², R³, and X¹ are as defined above and R⁴ is an alkylsulfonyloxy group or arylsulfonyloxy group) or reacting a compound having the formula (IVa):



(wherein R¹, R², R³, and X¹ are as defined above) a halogenating agent to synthesize a compound having the formula (VIb):




(wherein R¹, R², R³, and X¹ are as defined above and R⁵ is a halogen atom) reacting guanidine with a compound having the formula (VI):



to synthesize a compound having the formula (VII):


5



10 (wherein R^2 , R^3 , and X^1 are as defined above
and de-protecting the compound having the formula (VII)).

2. A compound having the formula (IV):

15




20

(wherein R^1 is an alkyl group having 1 to 4 carbon atoms,
 R^2 is a trimethylsilylethoxymethyl group, benzyloxymethyl
group, p-methoxybenzyloxymethyl group, methoxymethyl group,
25 methoxyethoxymethyl group, tert-butoxymethyl group, p-
anisylloxymethyl group, guaiacolmethyl group, tert-
butyldimethylsiloxymethyl group, dimethylthexylsiloxymethyl
group, or tert-butyldiphenylsiloxymethyl group, R^3 is a
trimethylsilylethoxymethyl group, benzyloxymethyl group, p-
30 methoxybenzyloxymethyl group, tert-butyldimethylsiloxy-
methyl group, dimethylthexylsiloxymethyl group, or tert-
butyldiphenylsiloxymethyl group, X^1 is a halogen atom or
hydrogen atom, and the dotted lines show a single bond
present at either one of the positions.)


35

3. A compound having the formula (VI):



5 (wherein R¹ is an alkyl group having 1 to 4 carbon atoms, R² is a trimethylsilylethoxymethyl group, benzyloxymethyl group, p-methoxybenzyloxymethyl group, methoxymethyl group, methoxyethoxymethyl group, tert-butoxymethyl group, p-anisyloxymethyl group, guaiacolmethyl group, tert-butyl dimethylsiloxy methyl group, dimethylhexylsiloxy methyl group, or tert-butyl diphenylsiloxy methyl group, R³ is a trimethylsilylethoxymethyl group, benzyloxymethyl group, p-methoxybenzyloxymethyl group, tert-butyl dimethylsiloxy methyl group, dimethylhexylsiloxy methyl group, or tert-butyl diphenylsiloxy methyl group, R⁶ is an alkylsulfonyloxy group, arylsulfonyloxy group, or halogen atom, and X¹ is a halogen atom or hydrogen atom.)

4. A compound having the formula (V):




25 (wherein R¹ is an alkyl group having 1 to 4 carbon atoms, R² is a trimethylsilylethoxymethyl group, benzyloxymethyl group, p-methoxybenzyloxymethyl group, methoxymethyl group, methoxyethoxymethyl group, tert-butoxymethyl group, p-anisyloxymethyl group, guaiacolmethyl group, tert-butyl dimethylsiloxy methyl group, dimethylhexylsiloxy methyl group, or tert-butyl diphenylsiloxy methyl group, R³ is a trimethylsilylethoxymethyl group, benzyloxymethyl group, p-

methoxybenzyloxymethyl group, tert-butyldimethylsiloxy-
methyl group, dimethylhexylsiloxymethyl group, or tert-
butyldiphenylsiloxymethyl group, and X^1 is a halogen atom
or hydrogen atom.)

5

5. A compound having the formula (VII):

10



15

(wherein R^1 is a trimethylsilylethoxymethyl group,
benzyloxymethyl group, p-methoxybenzyloxymethyl group,
methoxymethyl group, methoxyethoxymethyl group, tert-
20 butoxymethyl group, p-anisoxymethyl group, guaiacolmethyl
group, tert-butyldimethylsiloxymethyl group,
dimethylhexylsiloxymethyl group, or tert-
butyldiphenylsiloxymethyl group, R^3 is a trimethylsilyl-
ethoxymethyl group, benzyloxymethyl group, p-
25 methoxybenzyloxymethyl group, tert-butyldimethylsiloxy-
methyl group, dimethylhexylsiloxymethyl group, or tert-
butyldiphenylsiloxymethyl group, and X^1 is a halogen atom
or hydrogenate atom.)

30 Dated this 21st day of August 1998

SUNTORY LIMITED
By their Patent Attorneys

35 GRIFFITH HACK
Fellows Institute of Patent
Attorneys of Australia